Insulet Corporation (PODD)
Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Maria Chadwick - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Travis Steed - Bank of America Michael Polark - Wolfe Research Matt Taylor - Jefferies Chris Pasquale - Nephron Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer & Co. Joanne Wuensch - Citibank Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Insulet inventory pressures cloud annual revenue forecast raise
Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3.5% in extended trading.
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Q2 Earnings Miss Estimates
Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago.
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet expects to beat revenue estimates on strong insulin pump demand
Insulet reported preliminary second-quarter revenue above Wall Street estimates on Friday, as it benefited from strong demand for its insulin delivery devices.
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
Insulet (PODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Insulet Corporation saw a significant drop in stock price in 2023 due to concerns over the impact of GLP-1 weight loss drugs on the insulin pump industry. These fears seem to be largely overblown, however, meaning that Insulet is arguably still trading at a substantial discount to its true value as a company. Insulet's CEO believes that GLP-1 drugs are increasing the adoption of insulin, not decreasing it, suggesting a positive impact on the iCGM industry.
